Skye Bioscience Inc (SKYE) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are mixed, with bearish moving averages and neutral RSI. Options data suggests bearish sentiment with a high Option Volume Put-Call Ratio of 2.25. The company has no revenue, negative earnings, and a significant net loss, making it a risky investment. Additionally, there are no recent news catalysts, analyst ratings, or significant insider or hedge fund activity to support a buy decision. Given the lack of positive momentum and the investor's preference for long-term growth, it is recommended to hold off on investing in SKYE for now.

Technical Analysis

The MACD is positive and expanding, indicating potential bullish momentum. However, the RSI is neutral at 48.588, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 0.713 and 0.683, with resistance at 0.811 and 0.841. The pre-market price of 0.771 is near the pivot level of 0.762, suggesting limited immediate upside potential.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

MACD is positive and expanding, indicating potential bullish momentum.

Neutral/Negative Catalysts

Bearish moving averages, high Option Volume Put-Call Ratio (2.25), no revenue or profitability, and no significant insider, hedge fund, or congress trading activity. No recent news or analyst ratings to support a buy.

Financial Performance

In Q3 2025, the company reported no revenue, a net loss of -$12,754,660 (up 227.19% YoY), and an EPS of -0.32 (up 220.00% YoY). Despite improvements in net income and EPS, the company remains unprofitable with no revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

5 Analyst Rating

Wall Street analysts forecast SKYE stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.736

Low

Averages

14.33

High

Current: 0.736

Low

Averages

14.33

High

H.C. Wainwright

Ananda Ghosh

Buy

initiated

$20

AI Analysis

2025-09-30

Reason

H.C. Wainwright

Ananda Ghosh

Price Target

$20

AI Analysis

2025-09-30

initiated

Buy

Reason

H.C. Wainwright analyst Ananda Ghosh initiated coverage of Skye Bioscience with a Buy rating and $20 price target. The firm believes the company's nimacimab can introduce a new mechanism of longstanding interest to obesity clinicians. Nimacimab is a peripherally restricted monoclonal antibody targeting the CB1 receptor, designed to deliver the metabolic benefits of CB1 blockade without the psychiatric side effects that derailed earlier small molecule antagonists, the analyst tells investors in a research note. H.C. Wainwright views Sykes shares as undervalued at current levels.

Evercore ISI

Michael DiFiore

Outperform

initiated

$10

2025-08-14

Reason

Evercore ISI

Michael DiFiore

Price Target

$10

2025-08-14

initiated

Outperform

Reason

Evercore ISI analyst Michael DiFiore initiated coverage of Skye Bioscience with an Outperform rating and $10 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SKYE

Unlock Now

SKYE Should I Buy

SKYE Should I Buy

Should You Buy Skye Bioscience Inc (SKYE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch